Hints and tips:
Related Special Reports
...pharmaceutical ingredients (API) for hundreds of US and European drugmakers....
...Private equity groups Bain, Cinven, Carlyle and Permira have all acquired contract manufacturers or contract research organisations in recent years....
...“Collaboration is key to accelerating not just research and innovation globally, but also research excellence and capacity where these challenges are greatest.”...
...The company is aiming to develop a wide range of drugs and use its manufacturing scale to stay ahead of pharmaceutical rivals seeking to profit from consumer “hype” for weight loss products, he added....
...Its latest results show a 6 per cent fall in sales in the first quarter of 2024, which the company attributed to the strength of the Swiss franc and declining sales of its Covid-19 treatment Ronapreve....
...An interim review of the two clinical studies associated with Lykos’ PTSD treatment by the Institute for Clinical and Economic Review raised concerns about the design and conduct of the trials....
...Yet weight-loss treatments are not the only source of excitement in the world of pharmaceutical research. A class of molecules known as antibody-drug conjugates (ADCs) is generating buzz....
...Drugs companies issued 1,643 warnings of impending shortages in 2023, compared to 648 in 2020, the research found....
...Friday’s decision comes after the state of New Hampshire failed in its bid to receive FDA permission because it did not identify a pharmaceutical wholesaler which could deliver the drugs....
...There is a lot of data on profitable and hotly pursued research fields like cancer, for example. There is less on relatively neglected areas such as mental health or infectious diseases....
...The Indianapolis-based company has struck agreements with US government-backed manufacturer National Resilience and Italian producer BSP Pharmaceuticals for the filling and “finishing” of its injector pens...
...The Financial Times also previously reported that Eli Lilly had tapped contract manufacturers BSP Pharmaceuticals and Resilience to fill and finish its pens....
...and then distribute it under its own brand.Under the agreement, California will buy naloxone, a nasal spray that can reduce or reverse the effects of opioids, from generics manufacturer Amneal Pharmaceuticals...
...IDA’s Lohan warned of erecting new “barriers within the research and development cycle of new treatments” and possibly delaying market access....
...and health of our furry friends....
...make up the backbone of pharmaceutical care....
...These positive effects are evident in Vertex’s revenues, which more than doubled between 2019 and 2022, from $4.2bn to $8.9bn, the period covered by the FT-Statista ranking of the Americas’ 500 fastest-growing...
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...The writer is chief executive of the British Generic Manufacturers Association (BGMA) The UK is now in a global competition for medicines....
...Isomorphic Labs has partnerships with pharmaceutical companies Eli Lilly and Novartis....
...This created a surge in demand for lab monkeys, which regulators insist are important to prove the safety of drugs in early research because of their anatomical and behavioural similarities to humans, despite...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...But according to Holst, who has worked as a consultant for the company, it has struggled to develop small-molecule GLP-1 drugs, which are much easier and cheaper for manufacturers to produce at scale....
...The antitrust regulator wrote to 10 pharmaceutical manufacturers to inform them the agency had disputed their patents with the Food and Drug Administration, giving the companies a 30-day window to respond...
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
International Edition